LG Chem announced on Friday that it has received approval from the Korean Ministry of Food and Drug Safety (MFDS) for Xelenka, a Humira biosimilar for autoimmune disease treatment.
This approval comes about a year after LG Chem applied for the approval in December last year.
Xelenka is indicated for rheumatoid arthritis, psoriatic arthritis, uveitis in adults, Crohn's disease, and juvenile idiopathic arthritis in children.
Humira, the original drug developed by U.S. multinational pharmaceutical company AbbVie, generated sales of approximately $21.37 billion in 2022.
Other Korean pharmaceutical companies that have developed and licensed Humira biosimilars include Samsung Bioepis' Hadlima and Celltrion's Yuflyma.
"Xelenka is a biosimilar product developed as a control for Humira's high-concentration formulation, and has enhanced patient convenience by removing citrate, which can cause pain for patients," said LG Chem in a public filing. "We expect to provide patients with more options for treating autoimmune diseases through our previously launched etanercept biosimilar, Eucept, and Zelenka."
Following the news of Xelenka's approval in Korea, LG Chem's stock price was trading at 491,000 won ($379.4) as of 11:30 a.m. on Friday, up 5.8 percent from the previous day.
Related articles
- LG Chem to target prostate cancer and sexual precocity treatment market
- Is LG Chem’s purchase of land in Vacaville intended for biopharma manufacturing?
- Will LG Chem's cancer drug enter phase 3 trial in US?
- LG Chem begins developing 1st homegrown combined vaccine for infants
- LG Chem set to launch European clinical trial of gout drug tigulixostat
- LG Chem signs $250 million deal to license out monogenic obesity drug to Rhythm Pharmaceuticals
- LG Chem, Kyowa Kirin to co-market hyperphosphatemia drug
- Korean biosimilars of Humira step up offensives in domestic market
- LG Chem's subsidiary starts phase 3 study of head and neck cancer drug in US
- LG Chem opens aesthetic center in Shanghai